Letter

Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation

Andrea Dorst,[⊥] Regina Berg,[⊥] Christoph G. W. Gertzen, Daniel Schäfle, Katja Zerbe, Myriam Gwerder, Simon D. Schnell, Peter Sander, Holger Gohlke, and Karl Gademann*

Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

Homology Modelling

Semisynthetic Derivatives
> 20 examples

ABSTRACT: The glycoslated macrocyclic antibiotic fidaxomicin (**1**, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of *Clostridium difficile* infections (CDI). Among the main limitations for this compound, its low water solubility impacts further clinical uses. We report on the synthesis of new fidaxomicin derivatives based on structural design and utilizing an operationally simple one-step protecting group-free preparative approach from the natural product. An increase in solubility of up to 25-fold with largely retained activity was observed. Furthermore, hybrid antibiotics were prepared that show improved antibiotic activities.

KEYWORDS: Fidaxomicin, antibiotics, semisynthesis, homology modeling, water solubility

Fidaxomicin (**1**, tiacumicin B, lipiarmycin A3) is a glycosylated macrocyclic lactone produced by actinomycetes and has been isolated from four different soil bacteria.[1−7] Fidaxomicin shows good antibiotic activity in vitro against many Gram-positive bacteria, with minimum inhibitory concentration (MIC) values between 0.012 μg/mL and 0.25 μg/mL for *Clostridium difficile*,[8,9] a pathogen causing nosocomial diarrhea. Since 2011, fidaxomicin has been approved for the treatment of inflammations of the intestine caused by *C. difficile*.[10−12] Furthermore, excellent activity against multiresistant *Mycobacterium tuberculosis* (MIC values <0.008−0.045 μg/mL) and *Staphylococcus aureus* (MIC values 2−16 μg/mL) has been reported.[7,13] Due to the low water solubility of fidaxomicin (**1**) and in consequence its poor systemic absorption, its application for the treatment of systemic infections has not yet been achieved. The development of semisynthetic derivatives is therefore a promising approach to render this class of antibiotics available for such treatments of systemic infections, in particular by improving water solubility.

With regard to its aglycon ring system, fidaxomicin (**1**) structurally belongs to the macrocyclic lactone antibiotics (Figure 1), but features a larger 18-membered ring.[14,15] The aglycon is connected to a modified noviose (isobutyl ester instead of a methoxy group in 4″-position) as well as to a

rhamnose substituent, which is esterified to a dichlorohomoorsellinic acid subunit. The complex structure and the remarkable biological properties of fidaxomicin (**1**) aroused the interest of many research groups and led to several synthetic studies toward the preparation of the aglycon[16−20] and finally the first total synthesis of this natural product reported by some of us[21] and subsequently by others.[22] Furthermore, investigations of the mechanism of action revealed that fidaxomicin, in contrast to other macrolide antibiotics, does not affect ribosomal protein synthesis, but rather inhibits the transcription process catalyzed by bacterial RNA polymerase (RNAP).[8,23−30] In order to identify promising semisynthetic target molecules based on structural considerations, docking calculations of fidaxomicin on a homology model of *M. tuberculosis* RNAP as well as stability assays[31] under various conditions were carried out first.

**Figure 1.** Structure of fidaxomicin (tiacumicin B, lipiarmycin A3).

Figure 2. Interaction diagram of the predicted fidaxomicin binding mode in *M. tuberculosis* RNAP. The protein subunits are given in Greek letters. Gray circles around atoms show exposition to solvent. Orange circles show residues that lead to resistance when mutated; indirectly affected residues are displayed as hexagons.

We started our work with the prediction of the binding mode of fidaxomicin in a structural model of *M. tuberculosis* RNAP. We applied multitemplate homology modeling and a multimodel docking approach.[32,33] In the predicted complex, fidaxomicin forms one direct and three indirect interactions (mediated by water) with an RNAP residue whose mutation triggered resistance (Figure 2).[7,26,34−36] The dichlorohomoorsellinic acid is located outside the binding pocket and its phenolic hydroxy groups do not take part in any of these interactions. This led to the hypothesis that modifications at these positions represent a promising strategy when aiming to improve water solubility. Furthermore, these hydroxy groups are in proximity to the binding pocket of the antibiotic rifampicin (Figure S1) and we used our binding mode prediction to calculate the optimal linker length (24 atoms of a polyethylene glycol chain) to covalently connect the two antibiotics in order to target both binding sites at the same time. The actual binding mode of fidaxomicin in *M. tuberculosis* RNAP was recently elucidated

using cryo-electron microscopy (cryo-EM).[29,30] A comparison with our binding mode prediction revealed that the macrocycles are overlapping, but the resorcinol moieties point in opposite directions (Figure S2). However, the cryo-EM structure also revealed a solvent pocket around the dichlorohomoorsellinic acid subunit, thus further corroborating the hypothesis that this part is a suitable site for modifications.

According to our binding mode prediction, 3‴- and 5‴-positions displayed promising sites for modifications as they are exposed to the solvent. Furthermore, functionalizations in these positions turned out to be synthetically feasible without the use of any protecting group; thus, analogs were accessible with only one preparative step.[37] Therefore, fidaxomicin (**1**) was treated with different electrophiles under slightly basic conditions in DMF at elevated temperatures (Scheme 1). The products **2−10** were obtained as separable mixtures of mono- and disubstituted compounds (except **9b**[38]). It is noteworthy that the monosubstitutions were exclusively observed at 5‴-hydroxy

Scheme 1. Functionalization at Positions 3′′′ and 5′′′ of the Resorcinol Unit (Ns = Nosyl)

Scheme 2. Synthesis of a Fidaxomicin−Ciprofloxacin Hybrid

15a: R = H, **37%**
15b: R = Ciprofloxacin-acetate, **20%**

group since electronic effects might render this hydroxy group more nucleophilic. Under basic conditions, formation of trace amounts of isomers, which proved to be the transacylated isobutyric ester, could not be prevented.[31] After purification by preparative HPLC, the desired compounds were obtained in moderate to good yields (28−81%).

The substituents in compounds **2−7** were introduced for their high polarity and their common use in medicinal chemistry.

Scheme 3. Synthesis of the Fidaxomicin−Rifampicin Hybrid 19

The sulfonyl fluorides **8a/8b** were synthesized for their ability to form covalent bonds with the enzyme of interest (SuFEx-Click chemistry),[39] which might also be useful for MS-based studies on the binding site. In the context of a study on labeling of macromolecules with tetrazine moieties, we synthesized tetrazine-fidaxomicin **9b**.[38] Furthermore, we reacted the nosylated azidopropanol to obtain azide derivatives **10a/b**, which were used as a platform to connect several structurally diverse alkynes to the resorcinol moiety using Click chemistry (CuAAC) with a dicopper catalyst developed by Straub and co-workers[40] or commercially available Cu(I)OAc. Using azide **10a** as starting material, anilines **11**, PEG5-acid **12a**, and piperidin-amine **13a/b** were obtained, which showed improved water solubility in comparison with fidaxomicin (see below).

In addition to the derivatives discussed so far, hybrids of fidaxomicin with other antibiotics were synthesized. These either have different targets or interact with different binding sites within a common target. Fluoroquinolones are common components of hybrid antibiotics due to their stability in a great variety of reaction conditions and their broad spectrum of activity.[41,42] Modifications on the amine of the piperazine moiety were shown to barely influence their biological activity.[43] Therefore, this position was chosen for covalently connecting ciprofloxacin to fidaxomicin, thus expecting only minor effects on both molecules' biological properties. For the synthesis of the fidaxomicin-ciprofloxacin hybrid **15**, ciprofloxacin was first transformed into the corresponding bromoacetyl-ciprofloxacin **14** using bromoacetyl bromide (Scheme 2). Subsequent

exposure to basic conditions (K$_2$CO$_3$ in DMF) together with fidaxomicin resulted in the desired hybrid **15**.

As fidaxomicin and rifampicin share the same target enzyme (RNAP), but interact with different binding sites (Figure S1),[8] we synthesized a fidaxomicin−rifampicin hybrid. Based on our calculations on the predicted binding mode, an octaethylene glycol linker was deemed suitable in order to covalently connect the two antibiotics while retaining their ability to interact with their respective binding sites at the same time. Starting from fidaxomicin (**1**) and nosylated octaethylene glycol azide **16**, the octaethlyene glycol linker was introduced and azide **17** was then connected with literature-known alkynylated rifampicin **18**[44] using a Cu(I)-catalyst[40] to give the desired fidaxomicin-rifampicin hybrid **19** (Scheme 3).

We investigated the antibiotic activity of the synthesized derivatives on different bacterial strains such as *Bacillus subtilis* (DSM3256), *S. aureus* (ATCC29213), and *M. tuberculosis* by evaluation of the minimum inhibitory concentration (MIC) (see SI). Derivatives featuring promising antibiotic activity in these tests were further assessed for their antibiotic activity against several isolates of *C. difficile* (Table 1). Although some of the derivatives did not retain their antibiotic activity, it was demonstrated that large substituents on the resorcinol do not necessarily impair biological activity, which is shown by the good biological activities of derivatives **4a/b**, **5a**, **9b**, **13a**, and hybrids **15a** and **19**. Although derivatives **4a/b** and **13a/b** display decreased activity against *C. difficile*, some promising activity was observed against *M. tuberculosis, S. aureus*, and *B. subtilis*.

Table 1. Summary of the Minimum Inhibitory Concentrations (MIC) of Selected Derivatives

Compound	MIC in µg/mL												
	C. difficile ATCC 43255	*C. difficile* ATCC 700057	*C. difficile* BAA-1805	*C. difficile* BAA-1875	*C. difficile* ATCC 9689 (rt 001)	*C. difficile* 8260 (rt 017)	*C. difficile* 8282 (rt 017)	*C. difficile* 5680 (rt 027)	*C. difficile* 8264 (rt 027)	*C. difficile* 8290 (rt 078)	*M. tuberculosis*	*S. aureus* ATCC 29213	*B. subtilis* DSM3256
1	0.03	0.03	0.12	0.03	≤0.015	0.06	0.03	0.06	0.12	0.03	0.25	8−16	8−16
4a	>16	8	>16	8	2	16	8	>16	>16	16	2	16	32
4b	>16	16	>16	16	4	16	16	>16	>16	16	0.5−1	32	8
5a	0.5	0.25	0.5	0.5	0.03	0.03	0.06	0.5	0.5	0.25	1−2	>64	>64
9b	0.12	0.06	0.25	0.25	0.03	0.12	0.06	0.5	0.25	0.12	n.d.	n.d.	n.d.
13a	4	2	8	2	0.5	4	1	8	8	4	4-8	>64	>64
13b	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	16−32	>64	8
15a	0.03	0.06	0.12	0.06	≤0.015	0.03	0.03	0.12	0.12	0.12	1−2	>64	32 − 64
19	≤0.015	≤0.015	≤0.015	≤0.015	≤0.015	≤0.015	4	≤0.015	0.03	0.03	0.5	4	4−16
Rifampicin	≤0.015	≤0.015	≤0.015	≤0.015	≤0.015	>16	>16	≤0.015	≤0.015	≤0.015	0.004	0.008	0.25
Ciprofloxacin	>16	>16	>16	>16	16	>16	>16	>16	>16	>16	1	n.d.	n.d.

Moreover, compounds **5a** and **9b** retained excellent activity against *C. difficile*.

The fidaxomicin−rifampicin hybrid **19** shows an improved activity compared to fidaxomicin against all investigated strains and similar activity against *C. difficile* when compared to rifampicin. Interestingly, hybrid **19** retains its biological activity even against strains which are not susceptible to rifampicin (*C. difficile* 8260 and 8282). Though no antibiotic activity against *S. aureus* and *B. subtilis* has been observed, the fidaxomicin-ciprofloxacin hybrid **15a** retains its excellent activity against all *C. difficile* strains even though ciprofloxacin itself is inactive against the latter.

Additionally, we investigated the water solubility of the obtained derivatives at pH = 7 by HPLC. For this purpose, saturated solutions of the derivatives in phosphate buffer were prepared and the concentration was determined after filtration of the resulting suspensions. The results (Figure 3) provide evidence for higher water solubility of PEG-derivatives **7b** and **12a**, piperidinol **6a/b**, and piperidinamine **13b**. Thus, PEG5-acid **12a** displays 25-fold and amine **13b** 5-fold increase in water solubility, though its antibiotic activity is reduced.

In conclusion, apart from methylations[45] and benzylations[30] at the phenolic hydroxy groups, the new analogs presented here are, to our knowledge, the first examples of complex semi-synthetic derivatives of fidaxomicin obtained via phenolic modifications. Other derivatives recently reported are obtained by semisynthesis,[46−48] fermentation,[49,50] and fermentation of knockout mutants.[51−54] Based on our predictions of a binding mode of fidaxomicin in a homology model of *M. tuberculosis* RNAP, which suggested that modifications on the dichlor-ohomoorsellinic acid would be promising, several analogs have been synthesized and tested for their biological activity and


Figure 3. Solubility of selected derivatives in phosphate buffer (pH = 7).

water solubility. Some of these compounds showed improved water solubility with maintained antibiotic activity. The synthesized hybrid antibiotics **15** and **19** show improved activity compared to fidaxomicin, while also retaining activity against strains that show resistance against the attached antibiotic itself. Access to a great variety of derivatives of this complex natural product was achieved by using easy and reliable synthetic methods. These derivatives could provide an important contribution in ongoing efforts to reduce the rate of antibiotic resistance development in bacteria and broaden the scope of application of fidaxomicin.

■ ASSOCIATED CONTENT

ⓢ Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00381.

Supplementary Figures S1 and S2, experimental procedures and methods, characterization data, ^{1}H and ^{13}C NMR spectra, supplementary MIC tables, and computational details (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Karl Gademann − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland;* ⓞ orcid.org/0000-0003-3053-0689; Email: karl.gademann@chem.uzh.ch

Authors

Andrea Dorst − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland*

Regina Berg − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland*

Christoph G. W. Gertzen − *Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany*

Daniel Schäfle − *Institute of Medical Microbiology, University of Zurich, 8006 Zurich, Switzerland*

Katja Zerbe − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland*

Myriam Gwerder − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland*

Simon D. Schnell − *Department of Chemistry, University of Zurich, 8057 Zürich, Switzerland*

Peter Sander − *Institute of Medical Microbiology and National Center for Mycobacteria, University of Zurich, 8006 Zurich, Switzerland*

Holger Gohlke − *Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany;* ⓞ orcid.org/0000-0001-8613-1447

Complete contact information is available at:
https://pubs.acs.org/10.1021/acsmedchemlett.0c00381

Author Contributions

$^{\perp}$A.D. and R.B. contributed equally. The manuscript was written through contributions of all authors. A.D., R.B., and K.G. designed the study. A.D., R.B., and S.D.S. carried out the synthesis and characterization of the derivatives. C.G.W.G., and H.G. performed the homology modeling and computational studies. D.S. and P.S. developed the MIC tests for *M. tuberculosis* and performed the biological evaluation of the derivatives. K.Z. and M.G. performed the MIC tests against *S. aureus* and *B. subtilis*. A.D., R.B., and K.G. analyzed and discussed the results. A.D.,R.B., and K.G. wrote the manuscript. All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): A patent application (WO2019135010A1, EP18150671.8A) was filed Jan 8th, 2018 that includes antibiotics presented in this work.

■ ACKNOWLEDGMENTS

■ ABBREVIATIONS

CDI *C. difficile* infection; MIC minimum inhibitory concentration; RNAP RNA polymerase; cryo-EM cryo-electron microscopy; HPLC high performance liquid chromatography; PEG polyethylene glycol.

■ REFERENCES

(1) Parenti, F.; Pagani, H.; Beretta, G. Lipiarmycin, A New Antibiotic From Actinoplanes I. Description of the Producer Strain and Fermentation Studies. *J. Antibiot.* **1975**, *28*, 247−252.

(2) Coronelli, C.; White, R. J.; Lancini, G. C.; Parenti, F. Lipiarmycin, A New Antibiotic from Actinoplanes II. Isolation, Chemical, Biological and Biochemical Charaterization. *J. Antibiot.* **1975**, *28*, 253−259.

(3) Ōmura, S.; Imamura, N.; Ōiwa, R.; Kuga, H.; Iwata, R.; Masuma, R.; Iwai, Y. Clostomicins, New Antibiotics Produced by Micromonospora Echinospora Subsp. Armeniaca Subsp. Nov. I. Production, Isolation, and Physico-Chemical and Biological Properties. *J. Antibiot.* **1986**, *39*, 1407−1412.

(4) Takahashi, Y.; Iwai, Y.; Ōmura, S. Clostomicins, New Antibiotics Produced by Micromonospora Echinospora Subsp. Armeniaca Subsp. Nov. II. Taxonomic Study of the Producing Microorganism. *J. Antibiot.* **1986**, *39*, 1413−1418.

(5) Hochlowski, J. E.; Swanson, S. J.; Ranfranz, L. M.; Whittern, D. N.; Buko, A. M.; McAlpine, J. B. Tiacumicins, a Novel Complex of 18-Membered Macrolides II. Isolation and Structure Determination. *J. Antibiot.* **1987**, *40*, 575−588.

(6) Theriault, R. J.; Karwowski, J. P.; Jackson, M.; Girolami, R. L.; Sunga, G. N.; Vojtko, C. M.; Coen, L. J. Tiacumicins, a Novel Complex of 18-Membered Macrolide Antibiotics I. Taxonomy, Fermentation and Antibacterial Activity. *J. Antibiot.* **1987**, *40*, 567−574.

(7) Kurabachew, M.; Lu, S. H. J.; Krastel, P.; Schmitt, E. K.; Suresh, B. L.; Goh, A.; Knox, J. E.; Ma, N. L.; Jiricek, J.; Beer, D.; Cynamon, M.; Petersen, F.; Dartois, V.; Keller, T.; Dick, T.; Sambandamurthy, V. K. Lipiarmycin Targets RNA Polymerase and Has Good Activity against Multidrug-Resistant Strains of Mycobacterium Tuberculosis. *J. Antimicrob. Chemother.* **2008**, *62*, 713−719.

(8) Srivastava, A.; Talaue, M.; Liu, S.; Degen, D.; Ebright, R. Y.; Sineva, E.; Chakraborty, A.; Druzhinin, S. Y.; Chatterjee, S.; Mukhopadhyay, J.; Ebright, Y. W.; Zozula, A.; Shen, J.; Sengupta, S.; Niedfeldt, R. R.; Xin, C.; Kaneko, T.; Irschik, H.; Jansen, R.; Donadio, S.; Connell, N.; Ebright, R. H. New Target for Inhibition of Bacterial RNA Polymerase: Switch Region. *Curr. Opin. Microbiol.* **2011**, *14*, 532−543.

(9) Babakhani, F.; Gomez, A.; Robert, N.; Sears, P. Killing Kinetics of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium Difficile. *J. Med. Microbiol.* **2011**, *60*, 1213−1217.

(10) Erb, W.; Zhu, J. From Natural Product to Marketed Drug: The Tiacumicin Odyssey. *Nat. Prod. Rep.* **2013**, *30*, 161−174.

(11) Dorst, A.; Gademann, K. Chemistry and Biology of the Clinically Used Macrolactone Antibiotic Fidaxomicin. *Helv. Chim. Acta* **2020**, *103*, No. e2000038.

(12) Dorst, A.; Jung, E.; Gademann, K. Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin. *Chimia* **2020**, *74*, 270−273.

(13) Biedenbach, D. J.; Ross, J. E.; Putnam, S. D.; Jones, R. N. In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus Spp. and Enterococcus Spp. *Antimicrob. Agents Chemother.* **2010**, *54*, 2273−2275.

(14) Arnone, A.; Nasini, G.; Cavalleri, B. Structure Elucidation of the Macrocyclic Antibiotic Lipiarmycin. *J. Chem. Soc., Perkin Trans. 1* **1987**, 1353−1359.

(15) Serra, S.; Malpezzi, L.; Bedeschi, A.; Fuganti, C.; Fonte, P. Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-Ray Analysis. *Antibiotics* **2017**, *6*, 7.

(16) Glaus, F.; Altmann, K. H. Total Synthesis of the Tiacumicin B (Lipiarmycin A3/Fidaxomicin) Aglycone. *Angew. Chem., Int. Ed.* **2015**, *54*, 1937−1940.

(17) Miyatake-Ondozabal, H.; Kaufmann, E.; Gademann, K. Total Synthesis of the Protected Aglycon of Fidaxomicin (Tiacumicin B, Lipiarmycin A3). *Angew. Chem., Int. Ed.* **2015**, *54*, 1933−1936.

(18) Erb, W.; Grassot, J. M.; Linder, D.; Neuville, L.; Zhu, J. Enantioselective Synthesis of Putative Lipiarmycin Aglycon Related to Fidaxomicin/Tiacumicin B. *Angew. Chem., Int. Ed.* **2015**, *54*, 1929−1932.

(19) Jeanne-Julien, L.; Masson, G.; Astier, E.; Genta-Jouve, G.; Servajean, V.; Beau, J. M.; Norsikian, S.; Roulland, E. Synthesis of a Tiacumicin B Protected Aglycone. *Org. Lett.* **2017**, *19*, 4006−4009.

(20) Jeanne-Julien, L.; Masson, G.; Astier, E.; Genta-Jouve, G.; Servajean, V.; Beau, J.-M.; Norsikian, S.; Roulland, E. Study of the Construction of the Tiacumicin B Aglycone. *J. Org. Chem.* **2018**, *83*, 921−929.

(21) Kaufmann, E.; Hattori, H.; Miyatake-Ondozabal, H.; Gademann, K. Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin. *Org. Lett.* **2015**, *17*, 3514−3517.

(22) Norsikian, S.; Tresse, C.; François-Eude, M.; Jeanne-Julien, L.; Masson, G.; Servajean, V.; Genta-Jouve, G.; Beau, J.-M.; Roulland, E. Total Synthesis of Tiacumicin B: Implementing Hydrogen Bond Directed Acceptor Delivery for Highly Selective β-Glycosylations. *Angew. Chem., Int. Ed.* **2020**, *59*, 6612−6616.

(23) Talpaert, M.; Campagnari, F.; Clerici, L. Lipiarmycin: An Antibiotic Inhibiting Nucleic Acid Polymerases. *Biochem. Biophys. Res. Commun.* **1975**, *63*, 328−334.

(24) Sonenshein, A. L.; Alexander, H. B.; Rothstein, D. M.; Fisher, S. H. Lipiarmycin-Resistant Ribonucleic Acid Polymerase Mutants of Bacillus Subtilis. *J. Bacteriol.* **1977**, *132*, 73−79.

(25) Sonenshein, A. L.; Alexander, H. B. Initiation of Transcription in Vitro Is Inhibited by Lipiarmycin. *J. Mol. Biol.* **1979**, *127*, 55−72.

(26) Tupin, A.; Gualtieri, M.; Leonetti, J. P.; Brodolin, K. The Transcription Inhibitor Lipiarmycin Blocks DNA Fitting into the RNA Polymerase Catalytic Site. *EMBO J.* **2010**, *29*, 2527−2537.

(27) Artsimovitch, I.; Seddon, J.; Sears, P. Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis. *Clin. Infect. Dis.* **2012**, *55*, 127−131.

(28) Morichaud, Z.; Chaloin, L.; Brodolin, K. Regions 1.2 and 3.2 of the RNA Polymerase σ Subunit Promote DNA Melting and Attenuate Action of the Antibiotic Lipiarmycin. *J. Mol. Biol.* **2016**, *428*, 463−476.

(29) Boyaci, H.; Chen, J.; Lilic, M.; Palka, M.; Mooney, R. A.; Landick, R.; Darst, S. A.; Campbell, E. A. Fidaxomicin Jams Mycobacterium Tuberculosis RNA Polymerase Motions Needed for Initiation via RbpA Contacts. *eLife* **2018**, *7*, 1−19.

(30) Lin, W.; Das, K.; Degen, D.; Zhang, C.; Ebright, R. H.; Lin, W.; Das, K.; Degen, D.; Mazumder, A.; Duchi, D.; Wang, D.; Ebright, Y. W. Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). *Mol. Cell* **2018**, *70*, 60−71.

(31) Hattori, H.; Kaufmann, E.; Miyatake-Ondozabal, H.; Berg, R.; Gademann, K. Total Synthesis of Tiacumicin A. Total Synthesis, Relay Synthesis, and Degradation Studies of Fidaxomicin (Tiacumicin B, Lipiarmycin A3). *J. Org. Chem.* **2018**, *83*, 7180−7205.

(32) Gertzen, C. G. W.; Spomer, L.; Smits, S. H. J.; Häussinger, D.; Keitel, V.; Gohlke, H. Mutational Mapping of the Transmembrane Binding Site of the G-Protein Coupled Receptor TGR5 and Binding Mode Prediction of TGR5 Agonists. *Eur. J. Med. Chem.* **2015**, *104*, 57−72.

(33) Milić, D.; Dick, M.; Mulnaes, D.; Pfleger, C.; Kinnen, A.; Gohlke, H.; Groth, G. Recognition Motif and Mechanism of Ripening

Inhibitory Peptides in Plant Hormone Receptor ETR1. *Sci. Rep.* **2018**, *8*, 3890.

(34) Gualtieri, M.; Tupin, A.; Brodolin, K.; Leonetti, J. P. Frequency and Characterisation of Spontaneous Lipiarmycin-Resistant Enterococcus Faecalis Mutants Selected in Vitro. *Int. J. Antimicrob. Agents* **2009**, *34*, 605−616.

(35) Ebright, R. H. RNA-Exit Channel: Target and Method for Inhibition of Bacterial RNA. WO2005/001034, 2005.

(36) Babakhani, F.; Seddon, J.; Sears, P. Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium Difficile. *Antimicrob. Agents Chemother.* **2014**, *58*, 2934−2937.

(37) Gademann, K.; Berg, R.; Meier, A. Glycosylated Macrolides and Their Use as Antibiotics. WO 2019/135010 A1, 2019.

(38) Schnell, S. D.; Hoff, L. V.; Panchagnula, A.; Wurzenberger, M. H. H.; Klapötke, T. M.; Sieber, S.; Linden, A.; Gademann, K. 3-Bromotetrazine: Labelling of Macromolecules via Monosubstituted Bifunctional s-Tetrazines. *Chem. Sci.* **2020**, *11*, 3042−3047.

(39) Liu, Z.; Li, J.; Li, S.; Li, G.; Sharpless, K. B.; Wu, P. SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization. *J. Am. Chem. Soc.* **2018**, *140*, 2919−2925.

(40) Berg, R.; Straub, J.; Schreiner, E.; Mader, S.; Rominger, F.; Straub, B. F. Highly Active Dinuclear Copper Catalysts for Homogeneous Azide-Alkyne Cycloadditions. *Adv. Synth. Catal.* **2012**, *354*, 3445−3450.

(41) Hu, Y. Q.; Zhang, S.; Xu, Z.; Lv, Z. S.; Liu, M. L.; Feng, L. S. 4-Quinolone Hybrids and Their Antibacterial Activities. *Eur. J. Med. Chem.* **2017**, *141*, 335−345.

(42) Pokrovskaya, V.; Baasov, T. Dual-Acting Hybrid Antibiotics: A Promising Strategy to Combat Bacterial Resistance. *Expert Opin. Drug Discovery* **2010**, *5*, 883−902.

(43) Gootz, T. D.; Brighty, K. E. Fluoroquinolone Antibacterials: SAR, Mechanism of Action, Resistance, and Clinical Aspects. *Med. Res. Rev.* **1996**, *16*, 433−486.

(44) Cochrane, S. A.; Li, X.; He, S.; Yu, M.; Wu, M.; Vederas, J. C. Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria. *J. Med. Chem.* **2015**, *58*, 9779−9785.

(45) McAlpine, J. E.; Hochlowski, J. E. Dialkyltiacumicin Compounds. US E5,583,115, 1996.

(46) Wu, M.-C.; Huang, C.-C.; Lu, Y.-C.; Fan, W.-J. Derivatives of Tiacumicin B as Anti-Cancer Agents. US 2009/0110718 A1, 2008.

(47) Dorst, A.; Shchelik, I. S.; Schäfle, D.; Sander, P.; Gademann, K. Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics. *Helv. Chim. Acta* **2020**, *103*, No. e2000130.

(48) Dailler, D.; Dorst, A.; Schäfle, D.; Sander, P.; Gademann, K. Novel Fidaxomicin Antibiotics through Site-Selective Catalysis. *ChemRxiv* **2020**, DOI: 10.26434/chemrxiv.12593429.v1.

(49) Hochlowski, J. E.; Jackson, M.; Rasmussen, R. R.; Buko, A. M.; Clement, J. J.; Whittern, D. N.; McAlpine, J. B. Production of Brominated Tiacumicin Derivatives. *J. Antibiot.* **1997**, *50*, 201−205.

(50) Hochlowski, J. E.; Jackson, M.; McAlpine, J. B.; Rasmussen, R. R. Bromotiacumicin Compounds. US 5,767,096, 1998.

(51) Xiao, Y.; Li, S.; Niu, S.; Ma, L.; Zhang, G.; Zhang, H.; Zhang, G.; Ju, J.; Zhang, C. Characterization of Tiacumicin B Biosynthetic Gene Cluster Affording Diversified Tiacumicin Analogues and Revealing a Tailoring Dihalogenase. *J. Am. Chem. Soc.* **2011**, *133*, 1092−1105.

(52) Niu, S.; Hu, T.; Li, S.; Xiao, Y.; Ma, L.; Zhang, G.; Zhang, H.; Yang, X.; Ju, J.; Zhang, C. Characterization of a Sugar-O-Methyltransferase TiaS5 Affords New Tiacumicin Analogues with Improved Antibacterial Properties and Reveals Substrate Promiscuity. *ChemBioChem* **2011**, *12*, 1740−1748.

(53) Zhang, H.; Tian, X.; Pu, X.; Zhang, Q.; Zhang, W.; Zhang, C. Tiacumicin Congeners with Improved Antibacterial Activity from a Halogenase-Inactivated Mutant. *J. Nat. Prod.* **2018**, *81*, 1219−1224.

(54) Yu, Z.; Zhang, H.; Yuan, C.; Zhang, Q.; Khan, I.; Zhu, Y.; Zhang, C. Characterizing Two Cytochrome P450s in Tiacumicin Biosynthesis Reveals Reaction Timing for Tailoring Modifications. *Org. Lett.* **2019**, *21*, 7679−7683.